Kezar Life Sciences Inc Stock News

Kezar Life Sciences Inc (KZR) shares closed today at 0.7% below its 52 week high of $16.34, giving the company a market cap of $775M. The stock is currently up 202.3% year-to-date, up 183.3% over the past 12 months, and down 11.1% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 26.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -780.5% The company's stock price performance over the past 12 months beats the peer average by -686.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

In last trading session, Kezar Life Sciences Inc. (NASDAQ:KZR) saw 0.41 million shares changing hands with its beta currently measuring 0.11. Companys recent per share price level of $15.69 trading at $0.69 or 4.60% at ring of the bell on the day assigns it a market valuation of $729.90M. That closing price of KZRs stock Kezar Life Sciences Inc. (NASDAQ:KZR) Shares Are Up 13.45 Percent In A Week But Can The Gains Continue? Read More »

Kezar Life Sciences Inc (KZR) shares closed today at 1.3% below its 52 week high of $15.89, giving the company a market cap of $771M. The stock is currently up 200.6% year-to-date, up 184.2% over the past 12 months, and down 11.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 41.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -788.2% The company's stock price performance over the past 12 months beats the peer average by -715.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Kezar Life Sciences, Inc. (NASDAQ:KZR) shares reached a new 52-week high on Thursday . The company traded as high as $15.88 and last traded at $15.77, with a volume of 11332 shares changing hands. The stock had previously closed at $15.00. A number of equities research analysts recently weighed in on KZR shares. Wells Fargo []

Wall Street analysts forecast that Kezar Life Sciences, Inc. (NASDAQ:KZR) will announce ($0.29) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Kezar Life Sciences earnings. The highest EPS estimate is ($0.27) and the lowest is ($0.30). Kezar Life Sciences reported earnings of ($0.22) per share during the same [] The post -$0.29 Earnings Per Share Expected for Kezar Life Sciences, Inc. (NASDAQ:KZR) This Quarter appeared first on ETF Daily News .

Kezar Life Sciences, Inc. (NASDAQ:KZR)s share price was up 7.6% during trading on Thursday . The company traded as high as $13.89 and last traded at $13.77. Approximately 6,571 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 552,756 shares. The stock had previously closed at $12.80. A []

Kezar Life Sciences, Inc. (NASDAQ:KZR) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 3,590,000 shares, a growth of 99.4% from the November 15th total of 1,800,000 shares. Currently, 9.1% of the shares of the stock are sold short. Based on an average []

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) shot up 11.3% during mid-day trading on Tuesday . The company traded as high as $15.01 and last traded at $14.96. 19,833 shares traded hands during trading, a decline of 96% from the average session volume of 542,334 shares. The stock had previously closed at $13.44. A number []

Stock analysts at Wells Fargo & Company initiated coverage on shares of Kezar Life Sciences (NASDAQ:KZR) in a note issued to investors on Wednesday, The Fly reports. The brokerage set an overweight rating on the stock. Several other equities research analysts have also issued reports on the company. HC Wainwright lifted their price objective on []

Nuveen Asset Management LLC lifted its position in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 177,172 shares of the companys stock after purchasing an additional 2,154 shares during []

Millennium Management LLC raised its stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 2.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 801,361 shares of the companys stock after purchasing an additional 21,079 shares during the quarter. Millennium Management LLC owned []

The trading price of Kezar Life Sciences Inc. (NASDAQ:KZR) closed higher on Friday, November 19, closing at $13.97, 5.28% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Kezar Life Sciences, Inc. (NASDAQ:KZR) shares traded up 6.1% during mid-day trading on Thursday . The company traded as high as $13.63 and last traded at $13.58. 7,492 shares were traded during mid-day trading, a decline of 100% from the average session volume of 2,194,365 shares. The stock had previously closed at $12.80. A number []

Kezar Life Sciences (NASDAQ:KZR) had its target price boosted by HC Wainwright from $12.00 to $20.00 in a research report released on Tuesday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. A number of other brokerages have also recently commented on KZR. Jonestrading began coverage on Kezar Life Sciences […]

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) gapped down prior to trading on Wednesday . The stock had previously closed at $11.59, but opened at $11.25. Kezar Life Sciences shares last traded at $13.23, with a volume of 54,914 shares trading hands. Several research firms recently weighed in on KZR. HC Wainwright lifted their price []